Anticonvulsants - Antidepressants pharmacokinetic drug interactions: The role of the CYP450 system in psychopharmacology

Current Drug Metabolism

Volumn 9, Issue 8, 2008, Pages 730-737

  Mula, Marco ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Anticonvulsant drugs; Antidepressant drugs; Pharmacokinetic interaction

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CLOMIPRAMINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESIPRAMINE; ETIRACETAM; FELBAMATE; GABAPENTIN; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; IMIPRAMINE; LAMOTRIGINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VILOXAZINE;

AREA UNDER THE CURVE; CLINICAL TRIAL; COMORBIDITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; EMBASE; HUMAN; MEDLINE; MENTAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; POLYPHARMACY; PSYCHOPHARMACOLOGY; REVIEW; ANIMAL; DRUG INTERACTION; PHYSIOLOGY;

ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS;

EID: 58149343677     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920008786049311     Document Type: Review

References (76)

1. Gaitatzis, A.; Trimble, M.R.; Sander, J.W. (2004) The psychiatric comorbidity of epilepsy. Acta Neurol. Scand., 110(4), 207-220.
2. Kanner, A.M. (2005) Depression in epilepsy: a neurobiological perspective. Epilepsy Curr., 5, 21-27.
3. Preuter, C.; Norra, C. (2005) Mood disorders and their treatment in patients with epilepsy. J. Neuropsychiatry Clin. Neurosci., 17, 20-28.
4. Marcangelo, M.J.; Ovsiew, F. (2007) Psychiatric aspects of epilepsy. Psychiatr. Clin. North Am., 30, 781-802..
5. Amann, B.; Grunze, H.; Vieta, E.; Trimble, M. (2007) Antiepileptic drugs and mood stability. Clin EEG Neurosci. Clin. EEG Neurosci., 38(2), 116-123.
6. Mula, M.; Pini, S.; Cassano, G.B. (2007) The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J. Clin. Psychopharmacol., 27(3), 263-272.
7. Goedhard, L.E.; Stolker, J.J.; Heerdink, E.R.; Nijman, H.L.; Olivier, B.; Egberts, T.C. (2006) Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: A systematic review. J. Clin. Psychiatry, 67(7), 1013-1024.
8. McElroy, S.L.; Kotwal, R.; Keck, P.E.Jr. (2006) Comorbidity of eating disorders with bipolar disorder and treatment implications. Bipolar. Disord., 8(6), 686-695.
9. Stahl, S.M. Stahl's essential psychopharmacology 3rd edition. Cambridge University Press: Cambridge 2008.
10. Nutt, D.J. (2008) Relationship of neurotransmitters to the symptoms of major depressive disorder. J. Clin. Psychiatry, 69(Suppl E1), 4-7.
11. Berton, O.; Nestler, E.J. (2006) New approaches to antidepressant drug discovery: beyond the monoamines Nat. Rev. Neurosci., 7, 137-151.
12. Schatzberg, A.F.; Cole, J.O.; Debattista, C. Manual of clinical psychopharmacology 6th edition. American Psychiatric Publishing, Inc. Arlington 2007.
13. Morilak, D.A.; Frazer, A. (2004) Antidepressant and brain monoaminergic system: a dimensional approach to understanding the behavioral effects in depression and anxiety disorders. Int. J. Neuropsychopharmacol., 7, 193-218.
14. Nutt, D.J. (2006) The role of dopamine and norepinephrine in depression and antidepressant treatment. J. Clin. Psychiatry, 67 (Suppl 6), 3-8.
15. Rogawski, MA. Principles of antiepileptic drug action. In: Levy RH, Mattason RH, Meldrum BS, Perucca E. Antiepileptic drugs. 5th Edition. Philadelphia: Lippincott William & Wilkins, 2002:3-22.
16. Holtkamp, M.; Meierkord, H. (2007) Anticonvulsant, antiepileptogenic, and antiictogenic pharmacostrategies. Cell Mol. Life Sci., 64, 2023-2041.
17. D'Amico, D. (2007) Antiepileptic drugs in the prophylaxis of migraine, chronic headache forms and cluster headache: a review of their efficacy and tolerability. Neurol. Sci., 28(Suppl 2), S188-197.
18. Johannessen, S.I.; Landmark, C.J. (2008) Value of therapeutic drug monitoring in epilepsy. Expert Rev. Neurother., 8(6), 929-939.
19. Mula, M.; Monaco, F. (2002) Antiepileptic-antipsychotic drug interactions. A critical review of the evidence. Clin. Neuropharmacol., 25(5), 280-289.
20. Lynch, T.; Price, A. (2007) The effect of cythochrome P450 metabolism on drug response, interactions, and adverse effects. Am. Fam. Physician, 76(3), 391-396.
21. Nelson, D.R.; Koymans, L.; Kamataki, T.; Stegemn, J.J.; Feyereisen, R.; Waxman D.J.; Waterman, M.R.; Gotoh, O.; Coon, M.J.; Estabroon, R.W.; Gunsalus, I.C.; Nebert, D.W. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1-42.
22. Gonzalez, F.J. (1992) Human cytochromes P450: problems and prospects. Trends Pharmacol. Sci., 13, 346-352.
23. Brosen, K. (1995) Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin. Pharmacokinet., 29(Suppl 1), 20-25.
24. Greenblatt, D.J.; von Moltke, L.L.; Harmatz, J.S.; Shader, R.I. (1998) Drug interactions with newer antidepressants: role of human cytochromes P450. J. Clin. Psychiatry, 59(Suppl 15), 19-27.
25. Dresser, G.K.; Spence, J.D.; Bailey, D.G. (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet., 38, 41-57.
26. Tanaka, E. (1998) In. vivo age-related changes in hepatic drug-oxidizing capacity in humans. J. Clin. Pharmacol. Ther., 23, 247-255.
27. Perucca, E. (2006) Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin. Pharmacokinet., 45, 351-363.
28. Kashuba, A.D.; Bertino, J.S.J.; Rocci, M.L.J.; Kulawi, R.W.; Beck D.J.; Nafziger, A.N. (1998) Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP 3A activity as measured by phenotyping with intravenous midazolam. Clin. Pharmacol. Ther., 64(3), 269-277.
29. Ereshefsky, L.; Jhee, S.; Grothe, D. (2005) Antidepressant drug-drug interaction profile update. Drugs. R. D., 6, 323-336.
30. Spina, E.; Santoro, V.; D'Arrigo C. (2008) Clinically relevant pharmacokinetic drug interactions with second generation antidepressants: an update. Clin. Ther., 30, 1206-1227.
31. Kallow, W. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992.
32. Loscher, W.; Klotz, U.; Zimprich, F.; Schmidt, D. (2008) The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia., Jul 8 [Epub ahead of print].
33. Daly, K.; Cholerton, S.; Gregory, W.; Idle, J.R. (1993) Metabolic polymorphisms. Pharmacol. Ther., 57(2-3), 129-160.
34. Rudberg, I.; Hermann, M.; Refsum, H.; Molden, E. (2008) Serum concentrations of sertraline and N-desmethyl-sertraline in relation to cythocrome P 2C19 genotype in psychiatric patients. Eur. J. Clin. Pharmacol., Aug 3. [Epub ahead of print].
35. Rudberg, I.; Mohebi, B.; Hermann, M.; Refsum, H.; Molden, E. (2008) Impact of the ultrarapid cythochrome P 2C19* allele on serum concentration of escitalopram in psychiatric patients. Clin. Pharmacol. Ther., 83, 322-327.
36. Rudberg, I.; Hendset, M.; Uthus, L.H.; Molden, E.; Refsum, H. (2006) Eterozygous mutation in cythocrome P 2C19 significantly increases the concentration/dose ration of racemic citalopram and escitalopram (S-citalopram). Ther. Drug. Monit., 28, 102-105.
37. Normann, C.; Hesslinger, B.; Bauer, J.; Berger, M.; Walden, J. (1998) Significance of hepatic cytochrome P450 enzymes for psychopharmacology. Nervenartz., 69(11), 944-955.
38. Halpert, J.R. (1995) Structural basis of selective cytochrome P450 inhibition. Ann. Pharmacol. Toxicol., 35, 29-53.
39. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengherich, F.P. (1994) Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270(1), 414-423.
40. Lin, H.; Lu, A.Y.H. (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet., 35, 361-390.
41. Green, M.D.; Tephly, T.R. (1998) Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. Drug. Metab. Dispos., 26, 860-867.
42. Janicak, P.G. (1993) The relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. J. Clin. Psychiatry, 54(Suppl 9), 35-41.
43. Benedetti, M.S. (2000) Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam. Clin. Pharmacol., 14, 301-319.
44. Perucca, E. (2001) The clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fund. Clin. Pharmacol., 15, 405-417.
45. Ketter, T.A.; Post, R.M.; Parekh, P.I.; Worthington, K. (1995) Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. J. Clin. Psychiatry, 56, 471-475.
46. Perucca, E.; Manzo, L.; Crema, A. (1985) Pharmacokinetic interactions between antiepileptic and psychotropic drugs. In: Trimble MR (ed) The psychopharmacology of epilepsy. John Wiley & Sons, London, pp 95-105.
47. Monaco, F.; Cicolin, A. (1999) Interaction between anticonvulsant and psychoactive drugs. Epilepsia, 40(Suppl 10) S71-76..
48. Wong, S.L.; Cavanaugh, J.; Shi, H.; Awni, W.M.; Granneman, G.R. (1996) Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin. Pharmacol. Ther., 60, 48-53.
49. Fehr, C.; Grunder, G.; Hiemke, C.; Dahmen, N. (2000) Increase in serum clomipramine concentrations caused by valproate. J. Clin. Psychopharmacol., 20, 493-494.
50. Szymura-Oleksiak, J.; Wyska, E.; Wasieczko, A. (2001) Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. Psychopharmacology (Berl)., 154, 38-42.
51. Van Belle, K.; Sarre, S.; Ebinger, G.; Michotte, Y. (1995) Brain, liver and blood distribution kinetics of carbamazepine and its metabolic interaction with clomipramine in rats: a quantitative microdialysis study. J. Pharmacol. Exp. Ther., 272, 1217-1222.
52. Pisani, F.; Fazio, A.; Artesi, C.; Russo, M.; Trio, R.; Oteri, G.; Perucca, E.; Di Perri, R. (1992) Elevation of plasma phenytoin by Viloxazine in epileptic patients: a clinically significant drug interaction. J. Neurol. Neurosurg. Psychiatry, 55(2), 126-127.
53. Nemeroff, C.B.; De Vane, C.L.; Pollock, B.G. (1996) Newer anti-depressants and cytochrome P450 system. Am. J. Psychiatry, 153, 311-320.
54. Grimsley, S.R.; Jann, M.W.; Carter, J.G.; D'Maello, A.P.; D'Souza, M.J. (1991) Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin. Pharmacol. Ther., 50, 10-15.
55. Spina, E.; Avenoso, A.; Pollicino, A.M.; Caputi, A.P.; Fazio, A.; Pisani, F. (1993) Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther. Drug Monit., 15, 247-250.
56. Gidal, B.E.; Anderson, G.D.; Seaton, T.L.; Miyoshi, H.R.; Wilenksy, A.J. (1993) Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide. Ther. Drug Monit., 15, 405-409.
57. Andersen, B.B.; Mikkelsen, M.; Vesterager, A.; Dam, M.; Kristensen, H.B.; Pedersen, B.; Lund, J.; Mengel, H. (1991) No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res., 10, 201-204.
58. Leinonen, E.; Lepola, U.; Koponen, H. (1996) Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Pharmacopsychiatry, 29, 156-158.
59. Rapeport, W.G.; Williams, S.A.; Muirhead, D.C.; Dewland, P.M.; Tanner, T.; Wesnes, K. (1996) Absence of sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J. Clin. Psychiatry, 57(Suppl 1), 20-23.
60. Nelson, M.H.; Birnbaum, A.K.; Remmel, R.P. (2001) Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors. Epilepsy Res., 44, 71-82.
61. Mamiya, K.; Kojima, K.; Yukawa, E.; Higuchi, S.; Ieiri, I.; Ninomiya, H.; Tashiro, N. (2001) Phenytoin intoxication induced by fluvoxamine. Ther. Drug Monit., 23(1), 75-77.
62. Haselberger, M.B.; Freedman, L.S.; Tolbert, S. (1997) Elevated serum phenytoin concentrations associated with coadministration of sertraline. J. Clin. Psychopharmacol., 17, 107-109.
63. Rapeport, W.G.; Muirhead, D.C.; Williams, S.A.; Cross, M.; Wesnes, K. (1996) Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J. Clin. Psychiatry, 57(Suppl 1), 24-28.
64. Kaufman, K.R.; Gerner, R. (1998) Lamotrigine toxicity secondary to sertraline. Seizure, 7, 163-165.
65. Helland, A.; Spigset, O. (2007) Low serum concentrations of reboxetine in 2 patients treated with CYP3A4 inducers. J. Clin. Psychopharmacol., 27(3), 308-310.
66. Desta, Z.; Saussele, T.; Ward, B.; Blievernicht, J.; Li, L.; Klein, K.; Flockhart, D.A.; Zanger, U.M. (2007) Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics, 8(6), 547-558.
67. Ketter, T.A.; Jenkins, J.B.; Schroeder, D.H.; Pazzaglia, P.J.; Marangell, L.B.; George, M.S.; Callahan, A.M.; Hinton, M.L.; Chao, J.; Post, R.M. (1995) Carbamazepine but not valproate induces bupropion metabolism. J. Clin. Psychopharmacol., 15(5), 327-33.
68. Popli, A.P.; Tanquary, J.; Lamparella, V.; Masand, P.S. (1995) Bupropion and anticonvulsant drug interactions. Ann. Clin. Psychiatry, 7(2), 99-101.
69. Tekle, A.; al-Kamis, K.I. (1990) Phenytoin-bupropion interaction: effect on plasma phenytoin concentration in the rat. J. Pharm. Pharmacol., 42, 799-801.
70. Odishaw, J.; Chen, C. (2000) Effects of steady state bupropion on the pharmacokinetics of lamotrigine in healthy subjects. Pharmacotherapy, 20, 1448-1453.
71. Nawishy, S.; Hathaway, N.; Turner, P. (1981) Interactions of anticonvulsant drugs with mianserin and nomifensine. Lancet, 2, 871-872.
72. Sitsen, J.; Maris, F.; Timmer, C. (2001) Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. Eur. J. Drug. Metab. Phamacokinet., 26, 109-121.
73. Laroudie, C.; Salazar, D.E.; Cosson, J.P.; Cheuvart, B.; Istin, B.; Girault, J.; Ingrand, I.; Decourt, J.P. (2000) Carbamazepinenefazodone interaction in healthy subjects. J. Clin. Psychopharmacol., 20, 46-53.
74. Roth, L.; Bertschy, G. (2001) Nefazodone may inhibit the metabolism of carbamazepine: three case reports. Eur. Psychiatry, 16(5), 320-321..
75. Bialer, M. (2005) The pharmacokinetics and interactions of new antiepileptic drugs: an overview. Ther. Drug Monit., 27(6), 722-726..
76. Bialer, M.; Doose, D.R.; Murthy, B.; Curtin, C.; Wang, S.S.; Twyman, R.E.; Schwabe, S. (2004) Pharmacokinetic interactions of topiramate. Clin. Pharmacokinet., 43(12), 763-780..